Takanori Teshima

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

Jonathan U. Peled, Antonio L. C. Gomes, Sean M. Devlin et al. · New England Journal of Medicine · 2020 · 739 citations · Full text

Life Sciences, Immunology, Microbiology +12

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 527 citations · Full text

Medicine, Hematology, Oncology +12

Acute graft-versus-host disease does not require alloantigen expression on host epithelium

Takanori Teshima, Rainer Ordemann, Pavan Reddy et al. · Nature Medicine · 2002 · 519 citations

Life Sciences, Immunology, Pathology +15

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

Yoshikane Kikushige, Takahiro Shima, Shin‐ichiro Takayanagi et al. · Cell stem cell · 2010 · 482 citations · Full text

Medicine, Cell Biology, Oncology +10